Keywords: sepracor, bial, develop, epilepsy, drug, bia, 2-093
Sepracor and Bial to develop epilepsy drug BIA 2-093 for the USA in $175M deal
Article | 14 January 2008
Massachusetts, USA-based pharmaceutical firm Sepracor and Portugal's Bial have entered into an exclusive licensing agreement covering the latter's candidate anti-epileptic ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
